Press Releases Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
1.69 ^USD	-3.43%		-8.15%	-57.11%

May. 31	Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies	MT
May. 31	Invivyd Announces General Alignment with U.S. FDA on A Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Invivyd to Participate at the Jefferies Global Healthcare Conference	Jun. 03	GL
INVIVYD ANNOUNCES GENERAL ALIGNMENT WITH U.S. FDA ON A REPEATABLE, EXPEDIENT EMERGENCY USE AUTHORIZATION PATHWAY FOR THE PREVENTION AND TREATMENT OF SYMPTOMATIC COVID-19, BASED ON COMPACT CLINICAL PROGRAMS	Jun. 03	AQ
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies	May. 31	GL
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer	May. 31	GL
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)	May. 29	GL
Invivyd Elects Two New Independent Members to its Board of Directors	May. 22	GL
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference	May. 13	GL
Invivyd : Q1 2024 Invivyd Earnings Conference Call	May. 10	PU
Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights	May. 09	GL
Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback	May. 07	GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights	May. 02	GL
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights	May. 02	AQ
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position	Apr. 30	GL
Invivyd Announces CEO TransitionJeremy Gowler appointed Interim CEO	Apr. 15	AQ
INVIVYD ANNOUNCES CEO TRANSITION	Apr. 15	AQ
Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™	Apr. 15	GL
Invivyd Announces CEO Transition	Apr. 12	GL
Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million	Apr. 04	GL
Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights	Mar. 28	GL
Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial	Mar. 22	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Invivyd, Inc.

Equities

IVVD

US00534A1025

Press Releases

Filters